All control patients, including 18 patients with LMN and 12 patients with FSGS, were negative for anti-PLA2R and anti-THSD7A antibodies except for one patient with FSGS who was positive for anti-PLA2R (positive by ELISA, negative by IFI). This evidence concerns the gene THSD7A and focal segmental glomerulosclerosis.